INTRODUCTION
DNA binding proteins regulate gene expression. An alteration in gene expression can, in some cases, lead to cancer. Assays to quantitate this change can potentially lead to earlier diagnosis and treatment of the disease. Additionally, the future of medicine is likely to concentrate more on the molecular aspects of disease with the development of new drugs focused on gene expression and regulation (1, 2) . The p53 tumor suppressor protein controls the cell cycle of normal cells by recognizing damaged DNA, which results in growth arrest or induction of apoptosis (programmed cell death) (reviewed in References 3 and 4). In addition to its normal functions, p53 also plays a central role in the progression of many types of cancer. A number of genes change in human cancer; by far the most common mutation is in the p53 gene (5) . The mutations in p53 are often clustered in the DNA binding region or result in a truncated protein lacking this region (5-7). Studies with knockout mice lacking p53 indicate that they are prone to various types of cancer, and the p53 has been shown to be required in mouse thymocytes for apoptosis-induced by radiation (8) . Mutations in the p53 gene are associated with increased risk in developing metastatic breast disease, poorer prognosis of patients with small-cell lung cancer, and decreased sensitivity of cancer cells to chemotherapeutic agents (9) (10) (11) (12) . Thus, it may be possible that functional assays for p53 DNA binding could be used to monitor the progression of cancer and to determine appropriate modes of therapy. Generally DNA binding has been measured by electrophoretic mobility shift assays (EMSAs) or by filter binding (13, 14) , but neither is amenable to high-throughput screening. We have therefore chosen to develop a scintillation proximity assay (SPA) to measure DNA binding ( Figure 1A ). SPA beads, commercially available from GE Healthcare (Piscataway, NJ, USA), contain embedded scintillant that produces light when radioactive compounds are brought in proximity to the bead. Binding of these radioactively labeled compounds to the beads can occur through specific antibodies or other binding components (reviewed in Reference 15). This assay is fast partly because unbound material needs to be removed, as it does not contribute significantly to the signal. This assay has been used to measure serine kinase inhibitors and adenosine receptors-to name a few of the applications of this technology (16, 17) . In some cases, kits are available for these assays. We have used this approach to develop a SPA that measures DNA binding of human p53 protein, an assay that as yet does not have a convenient SPA kit ( Figure 1A ).
MATERIALS AND METHODS

Preparation of Labeled DNA and p53 Protein
We prepared a doublestranded DNA probe, sequence 5 ′ -( A ) 1 9 T G C C A A G G C T T G C C CGGGCAGGTCTGGCCT/AGGCC AGACCTGCCCGGGCAAGCCTTG GCA-3′, from the cyclin G promoter region that was known to bind p53 in a sequence-specific manner (18) , and used that to develop our SPA DNA binding assay. The DNA fragment was custom labeled using ( 3 H)TTP (GE Healthcare) and terminal transferase to a specific activity of 420 Ci/mmol (GE Healthcare). We prepared human p53 using recombinant baculovirus (kindly provided by K. Okamoto, Columbia University, New York, NY, USA) by infecting Sf9 insect cells and taking total cell extracts on different days postinfection. We quantitated the total protein in the cell extracts using bicinchoninic acid (Sigma-Aldrich, St. Louis, MO, USA) and the p53 protein specifically using a p53 enzymelinked immunosorbent assay (ELISA) kit (Oncogene Research Products, Cambridge, MA, USA).
Gel Shift and SPA of p53 DNA Binding
We confirmed DNA binding by the p53 using EMSAs following the method of Okamoto and Beach (18 Specific counts were determined by subtracting a reaction containing water instead of cell extract. We also found no significant difference between the background counts detected when using the extraction buffer. Other monoclonal antibodies against p53 (Oncogene Research Products) were also used at the same concentration as the pAb421 antibody. The poly(dA-dT) nonspecific DNA was replaced in some experiments with poly(dI-dC) or poly-Llysine at the same concentration. DNA containing a mutant form of the cyclin G promoter with three bases different from the wild-type, known to disrupt EMSA DNA binding (18) , was used to test specificity and had the sequence 5′-TGCCAAGGATTTCCCGGTCAGG TCCT/AGGCCAGACCTGACCGGG AAATCCTTGGCA-3′.
RESULTS AND DISCUSSION
p53 DNA Binding SPA Is Sensitive and Versatile DNA binding of the recombinant human p53 was first confirmed using standard EMSAs (data not shown), then monitored using SPA with 3 H-labeled DNA from the cyclin G promoter sequence that had been used previously to demonstrate p53 DNA binding (18) . Specific binding events could easily be detected over nonspecific binding ( Figure 1B) . To determine the sensitivity of the p53 DNA binding SPA, we compared the detection limit of this assay format with standard EMSAs. We found consistently that 0.5 ng p53 could be detected with a SPA signal having twice the background counts (Table 1A) . This is a similar sensitivity to the EMSA in our hands with this cell extract and DNA sequence (data not shown). The SPA signal could be saturated when the amount of p53 reached 20 ng using the amounts of materials indicated in the Materials and Methods section (data not shown). In addition, no p53 DNA binding in the SPA was detected using uninfected insect cell extracts (Table 1A ). The specificity of the p53 DNA complex was confirmed using competition experiments (see below). The p53-DNA bound complex on the SPA beads appeared very stable, as measurements of 80% of the initial counts were detected up to 50 h after addition of the beads (data not shown). Thus, this SPA has a similar sensitivity as EMSA to measure DNA binding, but is much faster. The SPA can give data in under 30 min while the EMSA requires at least 2 h. The SPA uses much less intensive radioactive atoms compared with the 32 P that is most commonly used for EMSA. Isotopes such as 125 I, 35 S, and 3 H are generally used as the SPA beads because they have good sensitivity with these lower energy radioactive compounds. Tritium also has the advantage in that it can be conveniently used over many months because it has a much longer half-life than 32 P. In addition, the configuration of the SPA using the TopCount instrument provides numerical data immediately for comparison. Bands detected on gels must first be scanned or analyzed to determine quantitative changes in DNA binding. 
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We also tested the effects of different nonspecific compounds. Substituting single-stranded poly(dA-dT) or poly-L-lysine for the double-stranded dA-dT had little effect on the counts obtained; however single-or double-stranded poly(dI-dC) reduced the SPA counts to 25%-35% of the original values (Table 1C and data not shown). The difference in DNA binding detected in the presence of poly(dI-dC) versus dAdT is curious, as other DNA binding experiments published with p53 used poly(dI-dC) as the nonspecific DNA (18) (19) (20) (21) (22) . We confirmed with EMSA that p53 DNA binding was also detected more efficiently when using dA-dT instead of dI-dC in addition to the labeled DNA fragment used for SPA (data not shown) so this difference was not something inherent with the SPA. This difference in the ability of poly(dA-dT) and poly(dI-dC) to affect specific binding may be due to the higher AT content of the binding oligonucleotide used in this assay because of the 19 adenines added at the 5′ for incorporation of the 3 H-thymidine.
For these assays, we have used primarily monoclonal antibody pAb421, as it has been shown to work in supershifting p53-DNA bound complexes using EMSAs (22-24 and data not shown). This antibody recognizes amino acids 371-380 of human p53, and is known to alter the conformation of p53 to promote DNA binding by mutant p53 proteins (22) (23) (24) . We used two additional monoclonal antibodies recognizing different regions of p53. When we used antibodies to other regions (antibody DO-1 recognizing amino acids 21-25 and antibody pAb246 recognizing amino acids 85-109), we noted similar or slightly stronger counts than detected with the pAb421 antibody (data not shown). The slight variations in the signal from the SPA using different anti-p53 antibodies may be related to what specific region is recognized by the Specific counts per minute (cpm) detected in the indicated samples after 5 h ± SEM (n = 2). Background counts with water in place of the extract gave counts of 270 ± 7 cpm, which was subtracted from the total counts to obtain the specific counts shown. SPA, scintillation proximity assay.
B. Additional Component Specific SPA Counts (cpm)
Control Counts (%)
Control (no additions) 11,100 ± 390 100 ± 3
With poly(dI-dC) 3390 ± 100 31 ± 3
With poly(dA-dT) 12,600 ± 160
With poly-L-lysine 11,000 ± 380 99 ± 3
Counts detected with specific components after 3.5 h ± SEM (n = 2). 
C. Competing Oligonucleotide
Association and Dissociation of DNA Binding by p53 Can Be Measured
One potential application for the SPA is to measure the dynamic nature of DNA binding. To test this, we first combined the buffer, protein extract, antibody, and SPA beads. After an equilibration time of 10 min, the labeled oligonucleotide (0.08 μCi) was added and samples read within 60 s. Initially, the counts from individual wells were kept as single values, as comparable wells were not counted at exactly the same time. There appeared to be a very fast association of the labeled DNA to the p53-anti-p53 antibody-protein A SPA bead complex, as the initial changes in signal detected were complete in 3 min (Figure 2A , 10-min preincubation). This was followed by a slow 10%-20% increase in the specific SPA counts detected until the maximum signal was reached in 2-6 h. Very similar counts were obtained when all the components were added at the same time (Figure 2A , 0-min preincubation). As these two configurations produced similar kinetics of binding, we hypothesize that the binding of the DNA to the p53 is the rate-limiting step in the SPA. To confirm the specificity of DNA binding detected in our SPA, we competed the signal with unlabeled mutant oligonucleotide (three base alteration, known not to compete for DNA binding by EMSA; Reference 18 and data not shown). As expected, the mutant sequence competed very poorly, not significantly reducing the SPA signal, while the wild-type sequence at lower concentrations competed very efficiently (Table 1C) . This assay was also used to measure the dissociation rate of DNA from p53. First, p53 was bound to the 3 Hlabeled DNA while monitoring the SPA counts for 100 min. Then, we added 10× or 100× of the unlabeled oligonucleotide and monitored the SPA counts for an additional 900 min. The counts obtained were compared with samples in which no additional DNA was added. The rate of loss of counts was substantial with the two different concentrations of excess unlabeled oligonucleotide ( Figure 2B ). Addition of 100× oligonucleotide resulted in a faster reduction in counts than when only 10× oligonucleotide was used (75 Duplicate wells were read approximately 1 min later so are plotted as separate data points. The association was fast and appeared to be limited primarily by the interaction of the DNA with p53 (n = 2 ± sem). (B) Dissociation rate. Samples contained 5.8 ng p53 with 0.08 μCi 3 H-labeled double-stranded oligonucleotide (0.19 pmol) with 1 mg SPA beads, and specific counts were determined for the first 100 min. Then for two duplicate samples, 1.9 pmol (add 10×) or 19 pmol (add 100×) unlabeled double-stranded oligonucleotide or nothing (no addition) were added to the samples, and the counts determined for another 900 min. A clear reduction in the SPA counts detected was observed with those samples given unlabeled oligonucleotide. The dissociation rate varied directly with the amount of competing nucleotide added (n = 2 ± sem). These are representative experiments of several performed. cpm, counts per minute.
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Short Technical Reports min versus 220 min for 50% reduction in SPA counts, respectively) ( Figure  2B) . The experiments to show the rate of binding and dissociation of the p53-DNA complex would not generally be possible with the normal EMSA, while it was relatively easily accomplished using the SPA we developed. In some cases, mutant forms of the p53 protein may be altered in either the association or the dissociation kinetics with DNA. Those differences could easily be visualized with our approach and would not be as straightforward to detect with a typical EMSA.
Conclusion
Thus, using a baculovirus produced human p53, we have developed a DNA binding assay for this protein with SPA technology that rivals existing EMSAs. Since this assay can be performed in a microtiter plate, it is amenable to high-throughput screening and could be modified from the present 96-well format to the 384-or 1536-well formats if one uses another detection means like a charge-coupled device (CCD) camera (16, 17) . This is not possible for EMSAs. Other recently published assays for p53 DNA binding take an approach similar to that for ELISAs (19, 20, 25) . Generally either biotinylated DNA is immobilized on plates coated with strepavidin, or the p53 is put on the plate through an antibody and bound biotinylated DNA is detected with strepavidin conjugated to an enzyme. These assays appear to have sensitivity similar to our assay, but require several incubation steps with washes in between, making the overall time much longer than with our SPA. One disadvantage of our assay is that it uses radioactively labeled nucleotides for the detection. But as these oligonucleotides can be labeled with the long lasting 3 H, the experiments can be continued for a number of years. Also, to make this assay work efficiently, it requires a microtiter plate scintillation counter or luminescence reader that may not be available in the laboratory. However, we feel that the advantages for speed and versatility may outweigh those disadvantages for some researchers. In addition, this assay can have the DNA binding protein immobilized on the beads like with the ELISA-like approaches listed above. Immobilized proteins are not as accessible to the free DNA, making it somewhat more difficult to detect binding. This does not have to be the case with our method as we have generally combined the binding protein and the labeled DNA first and then immobilized the complex on the detecting SPA beads. Future applications for our SPA may be in screening human cell extracts and tissues for p53 DNA binding activity. If successful, it may become an alternative to immunocytochemical methods to measure levels of p53. This type of SPA might also be incorporated into a direct screening format for compounds altering p53 DNA binding to identify drugs that could aid individuals with mutant forms of this tumor suppressor (1,2). Using our SPA, one could screen for drugs that alter the DNA binding on-or off-rate separately. This DNA binding SPA could easily be adapted to other DNA binding proteins as long as an antibody to the DNA binding protein is available and the DNA sequence recognized has been identified. There is one report of using this assay to measure DNA binding of the transcription factor NFκB from researchers in the Amersham Biosciences group that appeared prior to this work (26) .
